They found that TMEM16A overexpression correlated with EGFR pathway upregulation and poor prognosis as in other cancers, and, as expected, treating cells with EGF induced the release of intracellular calcium, TMEM16A-mediated chloride current, and SOCE mediated by Orai1 and TRPC1. The gene discussed is EGFR; the disease is cancer.